Trial Profile
A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 03 May 2022 Status changed from recruiting to completed.
- 16 Apr 2021 Planned End Date changed from 1 Nov 2021 to 30 Nov 2021.
- 16 Apr 2021 Planned primary completion date changed from 1 Oct 2021 to 31 Oct 2021.